In vitro and in silico characterization of the transport of selected perfluoroalkyl carboxylic acids and perfluoroalkyl sulfonic acids by human organic anion transporter 1 (OAT1), OAT2 and OAT3.

OAT1 OAT2 OAT3 PFAS molecular modelling transporter

Journal

Toxicology
ISSN: 1879-3185
Titre abrégé: Toxicology
Pays: Ireland
ID NLM: 0361055

Informations de publication

Date de publication:
27 Sep 2024
Historique:
received: 29 07 2024
revised: 18 09 2024
accepted: 26 09 2024
medline: 30 9 2024
pubmed: 30 9 2024
entrez: 29 9 2024
Statut: aheadofprint

Résumé

Perfluoroalkyl carboxylic acids (PFCAs) and perfluoroalkyl sulfonic acids (PFSAs) belong to the group of poly- and perfluoroalkyl substances (PFASs), which may accumulate in humans due to their limited excretion. To provide more insight into the active renal excretion potential of PFASs in humans, this work investigated in vitro the transport of three PFCAs (PFHpA, PFOA, PFNA) and three PFSAs (PFBS, PFHxS and PFOS) using OAT1-, OAT2- or OAT3-transduced human embryonic kidney (HEK) cells. Only PFHpA and PFOA showed clear uptake in OAT1-transduced HEK cells, while no transport was observed for PFASs in OAT2-transduced HEK cells. In OAT3-transduced HEK cells only PFHpA, PFOA, PFNA, and PFHxS showed clear uptake. To study the interaction with the transporters, molecular docking and dynamics simulation were performed for PFHpA and PFHxS, for which a relatively short and long half-life in humans has been reported, respectively. Docking analyses could not always distinguish the in vitro transported from the non-transported PFASs (PFHpA vs. PFHxS), whereas molecular dynamic simulations could, as only a stable interaction of the PFAS with the inner part of transporter mouth was detected for those that were transported in vitro (PFHpA with OAT1, none with OAT2, and PFHpA and PFHxS with OAT3). Altogether, this study presents in vitro and in silico insight with respect to the selected PFASs transport by the human renal secretory transporters OAT1, OAT2, and OAT3, which provides further understanding about the differences between the capability of PFAS congeners to accumulate in humans.

Identifiants

pubmed: 39343156
pii: S0300-483X(24)00242-7
doi: 10.1016/j.tox.2024.153961
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

153961

Informations de copyright

Copyright © 2024. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Jochem Louisse (J)

Wageningen Food Safety Research, Wageningen University and Research, Wageningen, the Netherlands. Electronic address: jochem.louisse@efsa.europa.eu.

Lorenzo Pedroni (L)

Department of Food and Drug, University of Parma, Parma, 43124 Italy.

Jeroen J M W van den Heuvel (JJMW)

Division of Pharmacology and Toxicology, Department of Pharmacy, Radboud University Medical Center, Nijmegen, the Netherlands.

Deborah Rijkers (D)

Wageningen Food Safety Research, Wageningen University and Research, Wageningen, the Netherlands.

Liz Leenders (L)

Wageningen Food Safety Research, Wageningen University and Research, Wageningen, the Netherlands.

Annelies Noorlander (A)

Wageningen Food Safety Research, Wageningen University and Research, Wageningen, the Netherlands.

Ans Punt (A)

Wageningen Food Safety Research, Wageningen University and Research, Wageningen, the Netherlands.

Frans G M Russel (FGM)

Division of Pharmacology and Toxicology, Department of Pharmacy, Radboud University Medical Center, Nijmegen, the Netherlands.

Jan B Koenderink (JB)

Division of Pharmacology and Toxicology, Department of Pharmacy, Radboud University Medical Center, Nijmegen, the Netherlands.

Luca Dellafiora (L)

Department of Food and Drug, University of Parma, Parma, 43124 Italy. Electronic address: luca.dellafiora@unipr.it.

Classifications MeSH